Study published confirming Ultibro Breezhaler superior to GSK's Seretide

16 May 2016
novartis-big

Swiss pharma giant Novartis (NOVN: VX) has confirmed the effectiveness of its Ultibro Breezhaler (indacaterol/glycopyrronium bromide) over Seretide (salmeterol/fluticasone) in preventing chronic obstructive pulmonary disease (COPD) exacerbations.

The Ultibro Breezhaler is being marketed on behalf of Novartis’ alliance partner Vectura Group (LSE: VEC), the developer of the delivery system, while Seretide is licensed by UK pharma major GlaxoSmithKline (LSE: GSK).

Results from the head-to-head FLAME study have been published in the New England Journal of Medicine. They showed not only the once-daily Ultibro Breezhaler’s superiority over twice-daily Seretide in preventing COPD exacerbations, but also over the widely used inhaled corticosteroid (ICS)/LABA combination.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical